Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,807,830
  • Shares Outstanding, K 168,712
  • Annual Sales, $ 957,800 K
  • Annual Income, $ 226,450 K
  • EBIT $ 90 M
  • EBITDA $ 97 M
  • 60-Month Beta 0.80
  • Price/Sales 3.81
  • Price/Cash Flow 31.68
  • Price/Book 4.58

Options Overview Details

View History
  • Implied Volatility 45.59% ( -8.15%)
  • Historical Volatility 37.60%
  • IV Percentile 35%
  • IV Rank 12.14%
  • IV High 127.33% on 04/16/25
  • IV Low 34.30% on 03/19/25
  • Put/Call Vol Ratio 0.25
  • Today's Volume 201
  • Volume Avg (30-Day) 338
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 29,536
  • Open Int (30-Day) 30,625

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.13
  • Number of Estimates 11
  • High Estimate 0.19
  • Low Estimate 0.05
  • Prior Year 0.17
  • Growth Rate Est. (year over year) -23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.69 +14.63%
on 10/13/25
23.58 -4.28%
on 11/06/25
+1.03 (+4.78%)
since 10/07/25
3-Month
19.69 +14.63%
on 10/13/25
26.65 -15.31%
on 08/28/25
-1.83 (-7.50%)
since 08/07/25
52-Week
13.40 +68.43%
on 04/09/25
26.65 -15.31%
on 08/28/25
+5.37 (+31.22%)
since 11/07/24

Most Recent Stories

More News
Acadia: Q3 Earnings Snapshot

Acadia: Q3 Earnings Snapshot

ACAD : 22.57 (+4.25%)
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

- Third quarter total revenues of $278.6 million, up 11% year-over-year - Narrowing and raising high end of NUPLAZID ® net product sales guidance...

ACAD : 22.57 (+4.25%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference ...

ACAD : 22.57 (+4.25%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference ...

ACAD : 22.57 (+4.25%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors...

ACAD : 22.57 (+4.25%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are...

ACAD : 22.57 (+4.25%)
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

ACAD : 22.57 (+4.25%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors...

ACAD : 22.57 (+4.25%)
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

Company to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time

ACAD : 22.57 (+4.25%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are...

ACAD : 22.57 (+4.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 24.12
2nd Resistance Point 23.42
1st Resistance Point 23.00
Last Price 22.57
1st Support Level 21.88
2nd Support Level 21.18
3rd Support Level 20.76

See More

52-Week High 26.65
Last Price 22.57
Fibonacci 61.8% 21.59
Fibonacci 50% 20.02
Fibonacci 38.2% 18.46
52-Week Low 13.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar